N
Nancy L. Keating
Researcher at Harvard University
Publications - 408
Citations - 22100
Nancy L. Keating is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 68, co-authored 360 publications receiving 18819 citations. Previous affiliations of Nancy L. Keating include University of North Carolina at Chapel Hill & Boston University.
Papers
More filters
Journal ArticleDOI
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
TL;DR: GnRH agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and cardiovascular disease and the benefits of GnRH agonists should be weighed against these potential risks.
Journal ArticleDOI
Patients’ Expectations about Effects of Chemotherapy for Advanced Cancer
Jane C. Weeks,Paul J. Catalano,Angel M. Cronin,Matthew Finkelman,Jennifer W. Mack,Nancy L. Keating,Deborah Schrag +6 more
TL;DR: Many patients receiving chemotherapy for incurable cancers may not understand that chemotherapy is unlikely to be curative, which could compromise their ability to make informed treatment decisions that are consonant with their preferences.
Journal ArticleDOI
Comparative effectiveness of minimally invasive vs open radical prostatectomy.
Jim C. Hu,Xiangmei Gu,Stuart R. Lipsitz,Michael J. Barry,Anthony V. D'Amico,Aaron Weinberg,Nancy L. Keating +6 more
TL;DR: Men undergoing MIRP vs RRP experienced shorter length of stay, fewer respiratory and miscellaneous surgical complications and strictures, and similar postoperative use of additional cancer therapies but experienced more genitourinary complications, incontinence, and erectile dysfunction.
Journal ArticleDOI
Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health
Alexi A. Wright,Nancy L. Keating,Tracy A. Balboni,Ursula A. Matulonis,Susan D. Block,Holly G. Prigerson +5 more
TL;DR: Interventions aimed at decreasing terminal hospitalizations or increasing hospice utilization may enhance patients' quality of life at the end of life (EOL) and minimize bereavement-related distress.
Journal ArticleDOI
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Paul L. Nguyen,Shabbir M.H. Alibhai,Shehzad Basaria,Anthony V. D'Amico,Philip W. Kantoff,Nancy L. Keating,David F. Penson,Derek J. Rosario,Bertrand Tombal,Matthew R. Smith +9 more
TL;DR: ADT is often a necessary component of the treatment of aggressive prostate cancer, yet it has known harms that can impair health and quality of life.